Trial Profile
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ExCel; MAP 3
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.
- 13 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.